CORONA Remedies Q4 FY26 Revenue Up 20.2% YoY

CORONA Remedies reported Q4 FY26 revenue growth of 20.2% YoY to ₹353.1 Cr and FY26 growth of 17.3% to ₹1,403.2 Cr.
The company acquired Wokadine® from Dr. Reddy's and 7 brands from Bayer Zydus, expanding into Povidone Iodine and infertility segments.
Bhayla facility received EAEU-GMP certification enabling entry into five Eurasian markets with a ~$25 billion opportunity.
Chronic and sub-chronic therapies contributed 72.3% of Q4 revenue with adjusted PAT growing 33.4% to ₹199.4 Cr in FY26.